[go: up one dir, main page]

YU23500A - 1'-/4-/1-(4-fluorfenil)-1h-indol-3-il/-1-butil/-spiro/ izobenzofuran-1(3h),4'-piperidin/hidrohalogenidi - Google Patents

1'-/4-/1-(4-fluorfenil)-1h-indol-3-il/-1-butil/-spiro/ izobenzofuran-1(3h),4'-piperidin/hidrohalogenidi

Info

Publication number
YU23500A
YU23500A YU23500A YU23500A YU23500A YU 23500 A YU23500 A YU 23500A YU 23500 A YU23500 A YU 23500A YU 23500 A YU23500 A YU 23500A YU 23500 A YU23500 A YU 23500A
Authority
YU
Yugoslavia
Prior art keywords
fluorophenyl
indole
piperidine
hydrohalogenides
butil
Prior art date
Application number
YU23500A
Other languages
English (en)
Inventor
Mork Niels
Lopez De Diego Heidi
Nielsen Ole
Original Assignee
H. Lundbeck A/S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S. filed Critical H. Lundbeck A/S.
Publication of YU23500A publication Critical patent/YU23500A/sh
Publication of RS49777B publication Critical patent/RS49777B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Ovaj pronalazak se odnosi na hidrohalogenid 1'-[4-[1-(4-fluorfenil)-1H-indol-3-il]-1-butil]-spiro[izobenzofuran-1(3H),4'-piperidina], farmaceutske sastave koji sadrže adicione soli kiselina i upotrebu istih za lečenje psihičkih i neuroloških bolesti.[The present invention relates to a hydrohalogenide of 1'- [4-[1- (4-fluorophenyl) -1i(H)-indole- 3-yl]-1- butyl]- spiroŠisobenzofuran-1(3i(H)),4'-piperidine], pharmaceutical compositions containing the acid addition salts and the use thereof for the treatment of psychic and neurological disorders.
YUP-235/00A 1997-11-07 1998-11-06 1'- [ 4- [ 1-(4-FLUORFENIL)-1H-INDOL-3-IL] -l-BUTIL ]-SPIRO [ IZOBENZOFURAN-1 (3H) ,4'-PIPERIDIN ] HIDROHALOGENIDI RS49777B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK126797 1997-11-07

Publications (2)

Publication Number Publication Date
YU23500A true YU23500A (sh) 2003-12-31
RS49777B RS49777B (sr) 2008-06-05

Family

ID=8102935

Country Status (39)

Country Link
US (2) US6844352B2 (sh)
EP (1) EP1044202B1 (sh)
JP (1) JP3605358B2 (sh)
KR (1) KR100399274B1 (sh)
CN (1) CN1105115C (sh)
AR (1) AR023010A1 (sh)
AT (1) ATE288918T1 (sh)
AU (1) AU749094B2 (sh)
BG (1) BG64906B1 (sh)
BR (1) BR9813949A (sh)
CA (1) CA2308745C (sh)
CZ (1) CZ288666B6 (sh)
DE (1) DE69828999T2 (sh)
DZ (1) DZ2642A1 (sh)
EA (1) EA002092B1 (sh)
EG (1) EG23791A (sh)
ES (1) ES2234162T3 (sh)
HK (1) HK1034075A1 (sh)
HR (1) HRP20000261B1 (sh)
HU (1) HUP0100991A3 (sh)
ID (1) ID25776A (sh)
IL (1) IL135723A (sh)
IS (1) IS2342B (sh)
JO (1) JO2052B1 (sh)
MA (1) MA25585A1 (sh)
NO (1) NO325920B1 (sh)
NZ (1) NZ504065A (sh)
PE (1) PE130299A1 (sh)
PL (1) PL190538B1 (sh)
PT (1) PT1044202E (sh)
RS (1) RS49777B (sh)
SK (1) SK285245B6 (sh)
TN (1) TNSN98201A1 (sh)
TR (1) TR200001267T2 (sh)
TW (1) TW483894B (sh)
UA (1) UA64769C2 (sh)
UY (1) UY25236A1 (sh)
WO (1) WO1999024436A1 (sh)
ZA (1) ZA9810116B (sh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030453A1 (es) * 2000-08-15 2003-08-20 Lundbeck & Co As H Composicion farmaceutica con contenido de 1' [4-[1-(4-fluorofenil)-1h-indol-3-il]-1-butil] espiro [isobenzofuran-1 (3h), 4'-piperidina]
AU2003263155A1 (en) * 2002-09-20 2004-04-08 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
US7863272B2 (en) 2003-06-12 2011-01-04 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
US20090306341A1 (en) * 2005-07-29 2009-12-10 Joachim Emmert LC/MS Blends Containing Ionizing Additives
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) * 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
ES2234162T3 (es) 2005-06-16
EA200000502A1 (ru) 2000-10-30
IS2342B (is) 2008-02-15
CZ288666B6 (cs) 2001-08-15
NO20002188L (no) 2000-06-14
BG104485A (en) 2001-01-31
SK6462000A3 (en) 2000-10-09
DE69828999D1 (de) 2005-03-17
IL135723A0 (en) 2001-05-20
JP3605358B2 (ja) 2004-12-22
PL340220A1 (en) 2001-01-15
HRP20000261B1 (en) 2009-04-30
EG23791A (en) 2007-08-13
CA2308745A1 (en) 1999-05-20
NO325920B1 (no) 2008-08-18
CN1105115C (zh) 2003-04-09
PT1044202E (pt) 2005-04-29
AU1022699A (en) 1999-05-31
HUP0100991A3 (en) 2003-03-28
CN1278823A (zh) 2001-01-03
HRP20000261A2 (en) 2001-04-30
PL190538B1 (pl) 2005-12-30
NO20002188D0 (no) 2000-04-27
AU749094B2 (en) 2002-06-20
TR200001267T2 (tr) 2000-09-21
CZ20001663A3 (cs) 2000-10-11
HK1034075A1 (en) 2001-10-12
US20050171135A1 (en) 2005-08-04
NZ504065A (en) 2002-05-31
RS49777B (sr) 2008-06-05
AR023010A1 (es) 2002-09-04
ZA9810116B (en) 1999-05-07
EP1044202A1 (en) 2000-10-18
TW483894B (en) 2002-04-21
TNSN98201A1 (fr) 2005-03-15
KR100399274B1 (ko) 2003-09-26
BG64906B1 (bg) 2006-08-31
JP2001522852A (ja) 2001-11-20
IL135723A (en) 2005-11-20
JO2052B1 (en) 1999-05-15
US20030055074A1 (en) 2003-03-20
EP1044202B1 (en) 2005-02-09
BR9813949A (pt) 2000-09-26
UA64769C2 (uk) 2004-03-15
EA002092B1 (ru) 2001-12-24
US6844352B2 (en) 2005-01-18
DZ2642A1 (fr) 2004-12-28
KR20010031791A (ko) 2001-04-16
PE130299A1 (es) 1999-12-16
ID25776A (id) 2000-11-02
IS5460A (is) 2000-04-18
CA2308745C (en) 2004-01-20
ATE288918T1 (de) 2005-02-15
WO1999024436A1 (en) 1999-05-20
HUP0100991A2 (hu) 2001-09-28
DE69828999T2 (de) 2005-07-21
MA25585A1 (fr) 2002-12-31
UY25236A1 (es) 2000-12-29
SK285245B6 (sk) 2006-09-07

Similar Documents

Publication Publication Date Title
YU23500A (sh) 1'-/4-/1-(4-fluorfenil)-1h-indol-3-il/-1-butil/-spiro/ izobenzofuran-1(3h),4'-piperidin/hidrohalogenidi
MY118163A (en) Aryl fused azapolycyclic compounds
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
HRP940890B1 (en) Novel(r)-5-carbamoyl-8-fluoro-3-n,n-disubstituted-amino-3,4-dihydro-2h-1-benozpyranes
MY117896A (en) Quinazoline derivatives
HU0301601D0 (en) Bis(n-substituted)-staurosporine derivatives, their use and pharmaceutical composition containing thereof
AU4204389A (en) 3-(aminopropyl)methyl phosphinic acid as a therapeutic agent and intermediates in its synthesis
MX9704777A (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y composiciones que los contienen.
UA27749C2 (uk) Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
HUT66971A (en) 4-amino-naphthyridine derivatives pharmaceutical compositions containing the same and process for the production of thereof
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
IL115073A (en) Use of 5-substituted pyridine-and hexahydroquinoline-3-carboxylic acid derivatives for the preparation of pharmaceutical compositions for the treatment of disorders of the central nervous system some such novel compounds their preparation and pharmaceutical compositions containing them
RU1833372C (ru) Cпocoб пoлучehия пpoизboдhыx 2,4,5-зameщehhыx бehзoлa
ZA948061B (en) Galanthamine derivatives a process for their preparation and their use as medicaments
HUT65626A (en) Process for producing of acridinedione derivatives and pharmaceutical compositions comprising them
EP0328634A4 (en) Pharmaceutical compositions for the treatment of psoriasis
WO1996031208A3 (de) Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten
HU9400908D0 (en) Pharmaceutical compositions for treatng skin disorders
HUT50769A (en) Process for producing 9-amino-1,4-metano-1,2,3,4-tetrahydro-acridine and compounds of such structure and pharmaceutical compositions containing them as active components
PL338242A1 (en) Novel compounds exhibiting an activity promoting differentation of neurones
HU9503099D0 (en) New piperazinyl-alkylthio-pyrimidine derivatives, pharmaceutical compositions containing them, and process for producing the active components
NZ335493A (en) Substituted 4-(6-fluoro-(1h)-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders
EP0911334A4 (en) CHINOLINMORPHINAN DERIVATIVES AND THEIR MEDICAL APPLICATION
ZA88639B (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones,a process for the preparation thereof,medicaments containing same and the use thereof,and also some intermediates formed in the preparation of the compounds mentioned
ATE314339T1 (de) Polyhydroxyphenolderivate und mittel zur vorbeugung und therapie von knochen- und knorpelkrankheiten die diese enthalten